,i  #aadth ,,congress  #b;d ,session    
,h4 ,r4 #fbhd  ,,in ,,the ,,house ,,of  
,,representatives  ,september #bh1      
#bjaf,mr4 ,smith of ,washington         
introduced the following bill2 which was
 referred to the ,committee on ,energy  
and ,commerce  ,a ,,bill  ,to amend the 
,federal ,food1 ,drug1 and ,cosmetic    
,act to prohibit the marketing of       
authorized generic drugs4  #a4 ,short   
title ,this ,act may be cited as the    
,eliminate ,price ,increases ,act of    
#bjaf or the ,,epi ,act4  #b4           
,prohibition of authorized generics     
,section #eje of the ,federal ,food1    
,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4
 #cee7 is amended by adding at the end  
the following3  7y7 ,prohibition of     
authorized generic drugs  7#a7 ,in      
general ,notwithstanding any other      
provision of this ,act1 no holder of a  
new drug application approved under     
subsection 7c7 shall manufacture1       
market1 sell1 or distribute an          
authorized generic drug1 direct or      

indirectly1 or authorize any other      
person to manufacture1 market1 sell1 or 
distribute an authorized generic drug4  
7#b7 ,authorized generic drug ,for      
purposes of this subsection1 the term   
authorized generic drug-- 7,a7 means any
 version of a listed drug 7as such term 
is used in subsection 7j77 that the     
holder of the new drug application      
approved under subsection 7c7 for that  
listed drug seeks to commence marketing1
 selling1 or distributing1 directly or  
indirectly1 after receipt of a notice   
sent pursuant to subsection 7j77#b77;,b7
 with respect to that listed drug2 and  
7,b7 does not include any drug to be    
marketed1 sold1 or distributed-- 7i7 by 
an entity eligible for exclusivity with 
respect to such drug under subsection   
7j77#e77;,b77iv72 or  7ii7 after        
expiration or forfeiture of any         
exclusivity with respect to such drug   
under such subsection 7j77#e77;,b77iv74 
4